Vascular News and Research

RSS

EETs may also drive growth and spread of cancer

A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.

20 Dec 2011

Blocking EETs may represent novel strategy for cancer therapy

Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.

20 Dec 2011

Combination of bevacizumab and chemoradiation safe, effective for nasopharyngeal carcinoma

The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.

17 Dec 2011

First reliable method to predict whether SSRIs work on depressed patients

Loyola University Medical Center researchers are reporting what could become the first reliable method to predict whether an antidepressant will work on a depressed patient.

16 Dec 2011

Microvascular stamp stimulates, directs blood vessel growth on wound surface

Researchers have developed a bandage that stimulates and directs blood vessel growth on the surface of a wound. The bandage, called a "microvascular stamp," contains living cells that deliver growth factors to damaged tissues in a defined pattern. After a week, the pattern of the stamp "is written in blood vessels," the researchers report.

16 Dec 2011

MHI cardiologists perform first clinical procedure in Canada using MitraClip system

The interventional cardiology team at the Montreal Heart Institute (MHI) recently conducted the first clinical procedure in Canada using the MitraClip system, which is designed to treat patients suffering from mitral valve failure, a very common heart defect that affects an estimated 1 out 5 people to various extents starting at the age of 55.

16 Dec 2011

F. nucleatum alters endothelial integrity and allows other bacteria to invade human body

A common oral bacteria, Fusobacterium nucleatum, acts like a key to open a door in human blood vessels and leads the way for it and other bacteria like Escherichia coli to invade the body through the blood and make people sick, according to dental researchers at Case Western Reserve University.

16 Dec 2011

FUJIFILM to acquire SonoSite

FUJIFILM Holdings Corporation, a diversified technology company that operates in healthcare, highly functional materials, and document solutions, announced today that it has entered into a definitive agreement with SonoSite, Inc., a pioneer and leader in bedside and point-of-care ultrasound technology, pursuant to which Fujifilm will acquire SonoSite for approximately $995 million.

15 Dec 2011

Experts warn expectant moms about dangers of common cold medicines during pregnancy

Experts in pregnancy and breastfeeding health at the California Teratogen Information Service (CTIS) Pregnancy Health Information Line warn expectant moms about the potential dangers of common cold medicines during pregnancy.

15 Dec 2011

Chemical disruption to key interaction shown to limit metastasis in test mice

Finding ways to counteract or disrupt the invasive nature of cancer cells, called "metastasis," has been a long-term goal of cancer researchers. Now, researchers at Moffitt Cancer Center in Tampa, Fla., have identified an interactive pathway that regulates metastases in some cancers that may be vulnerable to chemical targeting in order to prevent cancer cell proliferation and tumor growth.

14 Dec 2011

Researchers discover how statins promote breakdown of plaque in arteries

In a new study, NYU Langone Medical Center researchers have discovered how cholesterol-lowering drugs called statins promote the breakdown of plaque in the arteries. The study was published online by the journal PLoS One on December 6, 2011.

14 Dec 2011

JDRF initiates enrollment in metformin clinical study for type 1 diabetes

JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes (T1D) in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with T1D.

14 Dec 2011

Researchers identify interactive pathway that regulates cancer metastasis

14 Dec 2011

Baxter to acquire Synovis

Baxter International Inc. and Synovis Life Technologies, Inc. today announced a definitive agreement for Baxter to acquire Synovis, a leading provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures.

From Baxter International Inc. 14 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

IRIDEX announces data from MicroPulse laser therapy study on DME

IRIDEX Corporation today announced that data from a clinical study compiled over 10 years demonstrates the safety and efficacy of MicroPulse laser therapy for treating diabetic macular edema (DME) without the retina tissue damage associated with conventional laser therapy.

12 Dec 2011

Bluegrass Vascular commences enrollment in clinical study of Surfacer Inside-Out Access Catheter System

Bluegrass Vascular Technologies, a medical technology company focused on life-saving devices and methods for vascular access procedures, has announced patient enrollment in the first clinical study of its Surfacer Inside-Out Access Catheter System, a proprietary system that allows physicians to perform a novel "inside-out" approach to gain venous access.

9 Dec 2011

Abbott commences Absorb-XIENCE PRIME comparative clinical trial

Abbott today announced the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb™ bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME™ Everolimus Eluting Coronary Stent System.

9 Dec 2011

VDF, CDC and VDC to educate women about gender-specific DVT risks

Deep vein thrombosis (DVT) is a blood clot in the deep veins in the legs. These clots can break loose and travel to the lungs, causing a potentially fatal pulmonary embolism (PE). Even when they don't, they can cause permanent damage to the leg veins that results in long-term pain, swelling, and disability of the leg.

9 Dec 2011

MRI can predict breast cancer prognosis

Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

9 Dec 2011